Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 39 for:    lonafarnib

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03895528
Expanded Access Status : Available
First Posted : March 29, 2019
Last Update Posted : July 17, 2019
Sponsor:
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

Brief Summary:
This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies.

Condition or disease Intervention/treatment
Progeria HGPS Drug: Lonafarnib

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
Official Title: A Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid Laminopathy



Intervention Details:
  • Drug: Lonafarnib
    Farnesyl transferase inhibitor
    Other Name: FTI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Clinical diagnosis of HGPS or progeroid laminopathy by qualified medical doctor (based on common phenotype as described in Gordon 2015 and Merideth 2008). Confirmation with genetic testing is preferred but not required.
  • Adequate hepatic function as defined by SGPT (ALT) and SGOT (AST) ≤ 5 times upper limit of normal range for age

Exclusion Criteria:

  • Taking medications or foods that are known to be moderate or strong inducers or inhibitors of CYP3A4 or sensitive CYP3A substrates; or if a patient is taking one of these drugs and cannot safely discontinue or take an alternative drug, the dose of the inhibitor/inducer must be adjusted per the treating physician
  • Taking digoxin, a P-gp substrate with a narrow therapeutic window.
  • Severe renal impairment (GFR < 30 mL/min/1.73m2).
  • Uncontrolled infection.
  • Presence of any active clinically relevant medical condition that in the opinion of the treating physician would preclude patient from safely participating in the program.
  • Pregnant or breast-feeding or plan to become pregnant while on therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03895528


Contacts
Layout table for location contacts
Contact: Senior Director, Clinical Affairs (650) 279-9845 ProgeriaMA@eigerbio.com

Sponsors and Collaborators
Eiger BioPharmaceuticals

Publications:
Layout table for additonal information
Responsible Party: Eiger BioPharmaceuticals
ClinicalTrials.gov Identifier: NCT03895528     History of Changes
Other Study ID Numbers: EIG-EAP-LNF-001
First Posted: March 29, 2019    Key Record Dates
Last Update Posted: July 17, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Progeria
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Lonafarnib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action